Rüdiger Liersch

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

Enriqueta Felip, Nassar Altorki, Chi Zhou et al. · Annals of Oncology · 2022 · 14 citations

Oncology, High Pd-l1 Expression, Metronomic Therapy +5

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Caicun Zhou, Minu K. Srivastava, Hao Xu et al. · Journal for ImmunoTherapy of Cancer · 2023 · 14 citations · Full text

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Nadine Kutsch, Christian P. Pallasch, Eugen Tausch et al. · HemaSphere · 2022 · 13 citations · Full text

Tyrosine Kinase, Immunology, Pharmacotherapy +17